Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narlumosbart - CSPC Pharmaceutical Group

Drug Profile

Narlumosbart - CSPC Pharmaceutical Group

Alternative Names: Anti-RANKL monoclonal antibody - CSPC Pharmaceutical Group; Jinlitai; JMT-103; Narlumosbart - Shanghai Jinmante Biotechnology

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yong Shun Technology Development
  • Developer CSPC Pharmaceutical Group; Shanghai Jinmante Biotechnology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Giant cell tumour of bone
  • Phase II Bone metastases; Postmenopausal osteoporosis
  • Discontinued Malignant hypercalcaemia

Most Recent Events

  • 01 Feb 2024 Shanghai JMT-Bio plans a phase III trial for Bone metastases in China [SC,Injection] in April 2024 (NCT06221072)
  • 13 Oct 2023 Discontinued - Clinical-Phase-Unknown for Malignant hypercalcaemia in China (SC) prior to October 2023 (CSPC Pharmaceuticals pipeline, October 2023)
  • 06 Sep 2023 Registered for Giant cell tumours of bone (Inoperable/Unresectable) in China (SC) - First global approval
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top